Abstracts Archive - Page 1030 of 2607 - ACR Meeting Abstracts

Abstract Number: 1348 • 2019 ACR/ARP Annual Meeting
Impact of Tofacitinib on the Individual Components of the ACR Composite Score in Patients with Rheumatoid Arthritis: A Post Hoc Analysis of Phase 3 Trials
Louis Bessette¹, Maxime Dougados ², Eduardo Mysler ³, Mark Genovese ⁴, Cassandra Kinch ⁵, Kenneth Kwok ⁶, Tatjana Lukic ⁶, Tanya Girard ⁵, Pierre-Alexandre Landry ⁵ and Ronald van Vollenhoven ⁷, ¹Laval University, Quebec City, QC, Canada, ²Cochin Hospital, Paris, France, ³Organización Médica de Investigación, Buenos Aires, Argentina, ⁴Stanford University, Stanford, CA, ⁵Pfizer Canada ULC, Kirkland, QC, Canada, ⁶Pfizer Inc, New York, NY, ⁷Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. In clinical trials, standard criteria for measuring treatment efficacy in patients (pts) with…
Abstract Number: 1349 • 2019 ACR/ARP Annual Meeting
Earlier Biologic Initiation over Two Decades of Real World Observational Data from the RAPPORT Biologics Registry of Northern Alberta, Canada
Britney Jones¹, Bo Pan ¹, Joanne Homik ², Anthony Russell ², Walter P. Maksymowych ³, Jill Hall ¹ and Stephanie Keeling ¹, ¹University of Alberta, Edmonton, AB, Canada, ²University of Alberta, Edmonton, Canada, ³University of Alberta/CARE ARTHRITIS, Edmonton, AB, Canada
Background/Purpose: Rheumatoid (RA) and psoriatic arthritis (PsA) are inflammatory arthritides associated with significant potential functional disability if not well controlled. We reviewed the baseline demographic…
Abstract Number: 1350 • 2019 ACR/ARP Annual Meeting
Patient Disease Trajectories in Baricitinib-2 Mg-Treated Patients with Rheumatoid Arthritis and Inadequate Response to Biologic DMARDs
Mark Genovese¹, Michael Weinblatt ², Jianmin Wu ³, Bochao Jia ³, Amanda Quebe ³, Luna Sun ³, Yun-Fei Chen ³, Cameron Helt ³, A. Kirstin Bacani ³, Paulo Reis ³ and Janet Pope ⁴, ¹Stanford University, Stanford, CA, ²Brigham and Women's Hospital, Boston, MA, ³Eli Lilly and Company, Indianapolis, IN, ⁴Western University, London, ON, Canada
Background/Purpose: Baricitinib (BARI), a selective Janus kinase 1 and 2 inhibitor, is approved for the treatment of moderately-to-severely active RA in over 60 countries. In…
Abstract Number: 1351 • 2019 ACR/ARP Annual Meeting
Mortality of Rheumatoid Arthritis Patients, Treated to Target at Low Disease Activity: 17-years Follow-up of the BeSt Cohort
Johanna M Maassen¹, YPM Goekoop ², JHLM van Groenendael ³, WF Lems ⁴, PJSM Kerstens ⁵, Thomas Huizinga ⁶ and CF Allaart ¹, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ²Haga Hospital, 's-Gravenhage, Netherlands, ³Reumazorg Zuid West Nederland, Rozendaal, Netherlands, ⁴Amsterdam UMC, Amsterdam, Netherlands, ⁵Westfriesgasthuis, Hoorn, Netherlands, ⁶Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Rheumatoid arthritis is known to be associated with increased mortality over the years when compared to the general population. In the BeSt study, 508…
Abstract Number: 1352 • 2019 ACR/ARP Annual Meeting
Effects of Upadacitinib on Patient-Reported Outcomes After 24 Weeks in Patients with Active Rheumatoid Arthritis and an Inadequate Response to Conventional Synthetic or Biologic Disease-Modifying Anti-Rheumatic Drugs: Results from SELECT-NEXT and SELECT-BEYOND Phase 3 Studies
Martin Bergman¹, Namita Tundia ², Heidi Camp ², Sebastian Meerwein ³, Casey Schlacher ², Debbie Goldschmidt ⁴, Yan Song ⁵ and Vibeke Strand ⁶, ¹Drexel University College of Medicine, Stockholm, Sweden, ²AbbVie Inc., North Chicago, IL, ³AbbVie GmbH Co. KG, Ludwigshafen, Germany, Wiesbaden, Germany, ⁴Analysis Group, Inc., New York, NY, ⁵Analysis Group, Inc., Boston, MA, ⁶Division of Immunology/Rheumatology, Stanford University, Stanford, CA
Background/Purpose: Treatment with upadacitinib (UPA), a selective Janus kinase-1 (JAK-1) inhibitor, resulted in significant and clinically meaningful improvements in patient-reported outcomes (PROs) at Week 12…
Abstract Number: 1353 • 2019 ACR/ARP Annual Meeting
Impact of Smartphone Application Based Management in Rheumatoid Arthritis: SMART- RA Study
Ashit Syngle¹, Nidhi Garg ², Raveena Bhatia ³, Surbhi Rattan ⁴ and Kanchan Chauhan ⁴, ¹Healing Touch City Clinic/Fortis Multispeciality hospital, Chandigarh, Chandigarh, India, ²Chitkara College of Pharmacy, Chitkara University, Rajpura, India, ³Healing Touch City Clinic, Chandigarh, Chandigarh, India, ⁴Healing Touch City Clinic, Chandigarh, India
Background/Purpose: Rheumatoid arthritis (RA) treatment has improved considerably over the years. However, patient compliance remains critical to treatment outcomes. Patient compliance still poses challenges in…
Abstract Number: 1354 • 2019 ACR/ARP Annual Meeting
A Comparison of Convergent Validity and Sensitivity to Change of the Conventional Scoring Method to Alternative Scoring Methods of the Health Assessment Questionnaire in Rheumatoid Arthritis
Lai Ling Winchow ¹, Nimmisha Govind ¹, Eustasius Musenge ², Arvind Chopra ³, Thomas Huizinga ⁴ and Mohammed Tikly¹, ¹Chris hani baragwanath academic hospital, University of the Witwatersrand, Johannesburg, South Africa, ²School of Public Health, University of the Witwatersrand, Johannesburg, South Africa, ³Center for rheumatic diseases, Pune, India, ⁴Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: The HAQ disability index (HAQ-DI) is the most widely used disease-specific measure of physical disability in RA. This study explores the sensitivity to change…
Abstract Number: 1355 • 2019 ACR/ARP Annual Meeting
A Comparison of Clinical Improvement Following a Major Therapeutic Change Utilizing Updated Treatment Thresholds Defined by Three Different Disease Activity Measures
Grant Cannon¹, Wei Chen ¹, JIncheng Shen ², Neil Accortt ³, David Collier ⁴ and Brian Sauer ¹, ¹Salt Lake City VA Medical Center and Univeristy of Utah, Salt Lake City, UT, ²Univeristy of Utah, Salt Lake City, UT, ³Amgen, Thousand Oaks, CA, ⁴Amgen Inc., Thousand Oaks, CA
Background/Purpose: Despite ACR recommendations to initiate a major therapeutic change (MTC) in rheumatoid arthritis (RA) patients with moderate/severe disease activity, our recent work has shown…
Abstract Number: 1356 • 2019 ACR/ARP Annual Meeting
DAS28-CRP Cut-offs for High Disease Activity Assessment Is Lower Than DAS28-ESR in Rheumatoid Arthritis
Jacob Greenmyer¹, John Stacy ¹, James Beal ² and Erdal Diri ¹, ¹University of North Dakota, School of Medicine Health Sciences, Minot, ND, ²University of North Dakota, School of Medicine Health Sciences, Grandforks, ND
Background/Purpose: Rheumatoid arthritis (RA) disease activity and treatment response are usually assessed by using Disease Activity Score 28-joint count (DAS28), which can be calculated using…
Abstract Number: 1357 • 2019 ACR/ARP Annual Meeting
Leptin-adjustment of the Multi-biomarker Disease Activity (MBDA) Score Reduces the Influence of Adiposity
Joshua Baker¹, Jeffrey Curtis ², David Chernoff ³ and Michael George ⁴, ¹University of Pennsylvania, Philadelphia, PA, ²University of Alabama at Birmingham, Birmingham, AL, ³Myriad Genetics, Inc, Salt Lake City, UT, ⁴University of Pennsylvania, Philadelphia
Background/Purpose: Obesity and excess adiposity influence inflammatory markers and bias assessments of disease activity, most notably among women. A leptin-adjusted multi-biomarker disease activity (MBDA-LA) score…
Abstract Number: 1358 • 2019 ACR/ARP Annual Meeting
Defining Minimal Clinically Important Changes for the Patient Activity Scale-II
Joshua Baker¹, Patricia Katz ² and Kaleb Michaud ³, ¹University of Pennsylvania, Philadelphia, PA, ²University of California, San Francisco, san francisco, CA, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: The Patient Activity Scale (PAS)-II is an accepted disease activity measure used in the care of patients with rheumatoid arthritis (RA). A clinically important…
Abstract Number: 1359 • 2019 ACR/ARP Annual Meeting
Correlation of Ultrasound Guided Synovial Biopsies and Surgical Synovial Biopsies in Patients with Inflammatory Arthritis
Khin Lim¹, Ami Ben-artzi ¹, Lindsy Forbess ¹, Shimon Faber ² and Mariko Ishimori ¹, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Cedars Sinai Medical Center, Los Angeles, CA
Background/Purpose: Synovial biopsy is often performed when other methods of evaluation prove non-diagnostic in the assessment of persistent joint synovitis, whether in the setting of…
Abstract Number: 1360 • 2019 ACR/ARP Annual Meeting
Ultrasound Guided Synovial Biopsies Safely Aid in the Assessment of Inflammatory Arthritis
Khin Lim¹, Ami Ben-artzi ¹, Lindsy Forbess ¹, Swamy Venuturupalli ², John Jalas ³ and Mariko Ishimori ¹, ¹Cedars-Sinai Medical Center, Los Angeles, CA, ²Cedars Sinai Medical Center, Los Angeles, CA, ³Saint John Health Center, Los Angeles, CA
Background/Purpose: Synovial biopsies have an important role in the diagnostic evaluation of patients with undifferentiated inflammatory arthritis (UIA) whose clinical examination and blood and synovial…
Abstract Number: 1361 • 2019 ACR/ARP Annual Meeting
Utility of Rheumatoid Arthritis Impact of Disease (RAID) in Routine Care; Identification of Patients Achieving DAS28 Remission or Low Disease Activity, and Burden of Unmet Patient Reported Outcomes
Jatin Mistry ¹, Margaret Sibley ², Catherine Smith ³, Malama Sumbwanyambe ² and Patrick Kiely², ¹St George's University of London, London, United Kingdom, ²St George's University Hospitals NHS Trust, London, United Kingdom, ³St Georges University Hospitals NHS Foundation Trust, London, United Kingdom
Background/Purpose: ACR/EULAR guidelines recommend remission or low DAS28 as the treat to target goal for patients with rheumatoid arthritis (RA). Alternative patient reported outcomes include…
Abstract Number: 1362 • 2019 ACR/ARP Annual Meeting
Relationship Between Waking Functions and Disease Activity in Rheumatoid Arthritis Patients Analyzed by Wearable Device
Masahiro Tada¹, Yutaro Yamada ², Koji Mandai ² and Noriaki Hidaka ¹, ¹Osaka City General Hospital, Osaka, Japan, ²Osaka City University Graduate School of Medicine, Osaka, Japan
Background/Purpose: We reported that the prevalence of sarcopenia was 28% and locomotive syndrome was 52% in patients with rheumatoid arthritis (RA)1. It is unknown that…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].